Trial
NCT00995488
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
Celgene Corporation
Condition
Urothelial Cancer
Intervention
ABI-007 (Abraxane®)
Why stopped
Terminated prematurely due to low accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-09-11